Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted to SN‑38 inside cells. SN‑38 binds to the DNA‑topoisomerase I complex, preventing the re‑ligation of single‑strand DNA breaks during replication. This leads to accumulation of DNA damage and triggers apoptosis in rapidly dividing cancer cells.

The dose of Irinotecan Accord is individualized by the prescribing oncologist based on factors such as body surface area, disease stage, prior therapies, and organ function. Only a qualified healthcare professional should determine the appropriate regimen.

Irinotecan is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Use during breastfeeding is not recommended because the drug may be excreted in milk.

To request Irinotecan Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

The primary alternative within the same class is topotecan, another topoisomerase I inhibitor. Irinotecan generally shows higher activity in colorectal cancer, while topotecan is more often used for ovarian and small‑cell lung cancers. Compared with oxaliplatin‑based regimens, Irinotecan offers a different toxicity profile, with more gastrointestinal effects but less peripheral neuropathy.

Irinotecan Accord should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The solution must be kept in its original container, and any unused portion should be discarded according to local regulations after the recommended storage period.

Irinotecan Accord is given as an intravenous infusion by a qualified healthcare professional. The infusion is typically administered over 30 to 90 minutes, depending on the prescribed protocol, and may be repeated every two to three weeks as part of a treatment cycle.

The most critical adverse events include severe neutropenia or febrile neutropenia, life‑threatening diarrhea or colitis, significant liver enzyme elevations, and rare hypersensitivity reactions. Patients should be monitored closely for signs of infection, dehydration, or hepatic dysfunction throughout therapy.

Irinotecan Accord is contraindicated in patients with known hypersensitivity to irinotecan or its excipients, those with severe bone‑marrow suppression, and pregnant women unless the benefit outweighs the risk. Caution is also advised for individuals with significant hepatic or renal impairment.